TITLE:
A Study of CI-1012 in HIV-Infected Patients

CONDITION:
HIV Infections

INTERVENTION:
CI-1012

SUMMARY:

      The purpose of this study is to see if it is safe and effective to give CI-1012 to
      HIV-infected patients who do not have any symptoms of the disease. This study also examines
      how the body handles CI-1012.
    

DETAILED DESCRIPTION:

      Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients
      entered at each dose level studied.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to 60 Years
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Serologic evidence of infection with HIV-1.

          -  CD4+ cell count >= 200 cells/mm3.

          -  HIV-1 RNA >= 10,000 copies/ml.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions are excluded:

        Viral, fungal, or bacterial infection requiring therapy other than topical medications.

        Concurrent Medication:

        Excluded:

          -  Prophylactic systematic antibacterial, antifungal or antiviral agents.

          -  Antiretroviral therapy. NOTE:

          -  Patient must be willing to remain off antiretroviral therapy for 1 week after
             completing study medication.

        Prior Medication:

        Excluded:

          -  Experimental therapy for >= 4 weeks prior to initiation of study medication.

          -  Antiretroviral treatment for 3 weeks prior to initiation of study medication.

          -  Systemic steroids or anticancer agents for 4 weeks prior to initiation of study
             medication.
      
